Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Q1 growth driven by strong performance from EntrestoⓇ,
PluvictoⓇ, KesimptaⓇ and KisqaliⓇ
Q1 sales
Entresto
sacubitri/valsartan
Sales
USD million
Growth vs. PY
USD million
1,399
PLUVICTO™
211
209
Kesimpta
384
189
(ofatumumab)
KISQALI
415
176
ribociclib
Ⓒ SCEMBLIX®
76
51
(asciminib)
LEQVIO®
64
50
PROMACTA®
547
56
(eltrombopag)
Tafinlar. Mekinist.
458
55
d
ILARIS
328
43
(canakinumab)
istration
PIQRAY
116
(alpelisib) tablets
43
JAKAVI
ruxolitinib
414
25
Growth vs. PY
CC
306
32%
nm
GROWTH
100%
Strong growth
(+67% cc);
81%
expected to continue
202%
nm
15%
18%
19%
61%
13%
Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 35 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY.
nm not meaningful.
11 Investor Relations | Q1 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation